Related Experiment Video
Updated: Mar 7, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges
F Cappuzzo1, L Toschi, G Finocchiaro
1Department of Oncology-Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan - Italy.
Abstract:
The epidermal growth factor receptor (EGFR) plays a key role in cancer development and progression in several human malignancies including non-small cell lung cancer (NSCLC). Several strategies aimed at inhibiting the EGFR have been investigated in the last years, including the use of small tyrosine kinase inhibitors (TKIs) directed against the intracellular domain of the receptor and monoclonal antibodies targeting its extracellular portion. Subgroups of patients who are more likely to respond to TKIs have been identified based on both clincal and biological features. Never-smoking history has emerged as the most relevant clinical characteristic predictive of response to TKIs in NSCLC, while presence of drugsensitive EGFR mutations and EGFR gene gain represent critical biological variables associated with an improved outcome for patients exposed to these agents. Recent studies have highlighted the existence of biological factors involved in intrinsic and acquired resistance to TKIs, including k-ras, HER-2 and EGFR exon 20 mutations. Increasing knowledge of EGFR biology and drug-receptor interactions will allow to identify individuals who are likely to derive a clinical benefit from the proposed targeted therapy, sparing refractory patients expensive and potentially toxic treatment.
Insights
Identifying predictive biomarkers for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) improves patient outcomes. Never-smoking history and specific EGFR mutations predict TKI response.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The epidermal growth factor receptor (EGFR) is crucial in non-small cell lung cancer (NSCLC) development and progression.
- Targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are used to inhibit EGFR.
- Patient selection for EGFR-targeted therapies is critical for treatment efficacy.
Purpose of the Study:
- To identify clinical and biological factors that predict patient response to EGFR-targeted therapies in NSCLC.
- To understand the mechanisms of intrinsic and acquired resistance to EGFR TKIs.
- To guide personalized treatment strategies for NSCLC patients based on EGFR status.
Main Methods:
- Review of clinical and biological features associated with TKI response in NSCLC.
- Analysis of genetic mutations (e.g., k-ras, HER-2, EGFR exon 20) related to TKI resistance.
- Exploration of EGFR biology and drug-receptor interactions.
Main Results:
- Never-smoking history is a significant clinical predictor of TKI response in NSCLC.
- Drug-sensitive EGFR mutations and EGFR gene gain are associated with improved outcomes with TKIs.
- Specific mutations (k-ras, HER-2, EGFR exon 20) contribute to intrinsic and acquired resistance to TKIs.
Conclusions:
- Personalized medicine approaches, guided by predictive biomarkers, can optimize TKI therapy for NSCLC.
- Understanding resistance mechanisms is key to developing future treatment strategies.
- Identifying responders and non-responders spares patients unnecessary toxicity and cost.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase